NASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $23.93 +0.63 (+2.70%) (As of 07/5/2024 ET) Add Share Share Today's Range$22.94▼$24.7050-Day Range N/A52-Week Range$18.00▼$27.11Volume171,016 shsAverage Volume271,518 shsMarket Capitalization$846.64 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartInsider TradesTrendsStock AnalysisAnalyst ForecastsChartInsider TradesTrends Get Rapport Therapeutics alerts: Email Address Rapport Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.3% Upside$35.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 11 Articles This WeekInsider TradingAcquiring Shares$1.08 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.72) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector559th out of 884 stocks 3.5 Analyst's Opinion Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRapport Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Rapport Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for RAPP. Previous Next 0.0 Dividend Strength Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RAPP. Previous Next 3.9 News and Social Media Coverage News SentimentRapport Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Rapport Therapeutics this week, compared to 0 articles on an average week.Search Interest23 people have searched for RAPP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,079,665.00 in company stock and sold $0.00 in company stock.Read more about Rapport Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rapport Therapeutics are expected to decrease in the coming year, from ($2.72) to ($2.81) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Hedge Funds Reveal A.I. Moonshot CoinsFind out what the world's biggest crypto hedge funds are buying in 2024 at... The Crypto Hedge Fund Summit Airing Live: February 7th - 8th, 2024Click here to register now About Rapport Therapeutics Stock (NASDAQ:RAPP)Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Read More RAPP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAPP Stock News HeadlinesJuly 4 at 8:20 AM | insidertrades.comJames Healy Purchases 44,032 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockJuly 5 at 4:01 PM | insidermonkey.comHedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and MoreJuly 5, 2024 | Crypto 101 Media (Ad)Top Hedge Funds Reveal A.I. Moonshot CoinsFind out what the world's biggest crypto hedge funds are buying in 2024 at... The Crypto Hedge Fund Summit Airing Live: February 7th - 8th, 2024July 3 at 4:46 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Coverage Initiated by Analysts at TD CowenJuly 3 at 3:29 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Receives New Coverage from Analysts at Stifel NicolausJuly 2 at 8:20 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Research Coverage Started at Jefferies Financial GroupSee More Headlines Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CUSIPN/A CIKN/A WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$35.00 Low Stock Price Target$35.00 Potential Upside/Downside+43.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,380,000Free FloatN/AMarket Cap$862.92 million OptionableN/A BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report InsidersJames HealyBought 44,032 shares on 7/1/2024Total: $1.08 M ($24.52/share)View All Insider Transactions RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $25.01 on January 1st, 2024. Since then, RAPP shares have decreased by 4.3% and is now trading at $23.93. View the best growth stocks for 2024 here. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an initial public offering on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. When does Rapport Therapeutics' quiet period expire? Rapport Therapeutics' quiet period expires on Wednesday, July 17th. Rapport Therapeutics had issued 8,000,000 shares in its public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. During Rapport Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RAPP) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored7 Great Summertime Stock Plays for YouWe’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio…...StockEarnings | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
